Figure 3From: Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients Foxp3 + Treg trend in one patient during the first cycle of temozolomide: basal (1 ), after temozolomide (2) and after IL - 2 (3) . Back to article page